{"prompt": "['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', 'Appendix 6', 'Contraceptive Guidance and Collection of Pregnancy', 'Information', 'Definitions:', 'Woman of childbearing potential (WOCBP)', 'A woman is considered fertile following menarche and until becoming postmenopausal unless', 'permanently sterile (see below).', 'If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot be', 'confirmed before first dose of study intervention, additional evaluation should be considered.', 'Women in the following categories are not considered WOCBP', '1. Premenarchal', '2. Premenopausal female with 1 of the following:', 'Documented hysterectomy.', 'Documented bilateral salpingectomy.', 'Documented bilateral oophorectomy.', 'For individuals with permanent infertility due to an alternate medical cause other than the', 'above, (eg, mullerian agenesis, androgen insensitivity), Investigator discretion should be', 'applied to determining study entry.', \"Note: Documentation can come from the study center personnel's review of the subject's\", 'medical records, medical examination, or medical history interview.', '3. Postmenopausal female:', 'A postmenopausal state is defined as no menses for 12 months without an alternative', 'medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal', 'range may be used to confirm a postmenopausal state in women not using hormonal', 'contraception or hormonal replacement therapy (HRT). However, in the absence of', '12 months of amenorrhea, a single FSH measurement is insufficient.', 'Females on HRT and whose menopausal status is in doubt will be required to use 1 of the', 'non-estrogen hormonal highly effective contraception methods if they wish to continue', 'their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation', 'of postmenopausal status before study enrollment.', '29 October 2019', '74']['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', 'Contraception Guidance', 'Male subjects', 'Male subjects with female partners of childbearing potential are eligible to participate if they', 'agree to ONE of the following (during the protocol-defined time frame in Section 5.1):', '-', 'Are abstinent from penile-vaginal intercourse as their usual and preferred lifestyle', '(abstinent on a long-term and persistent basis) and agree to remain abstinent.', '-', 'Agree to use a male condom plus partner use of a contraceptive method with a failure', 'rate of <1% per year when having penile-vaginal intercourse with a WOCBP who is', 'not currently pregnant.', 'In addition, male subjects must refrain from donating sperm for the duration of the study and', 'for 220 days (which includes the duration of relevant exposure plus the duration of sperm', 'cycle) after the last dose of study treatment.', 'Male subjects with a pregnant or breastfeeding partner must agree to remain abstinent from', 'penile-vaginal intercourse or use a male condom during each episode of penile penetration', 'for the duration of the study and for 220 days (which includes the duration of relevant', 'exposure plus the duration of sperm cycle) after the last dose of study treatment.', 'Female subjects', 'Female subjects of childbearing potential are eligible to participate if they agree to use highly', 'effective methods of contraception consistently and correctly as described in the table below.', '29 October 2019', '75']['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', 'Highly Effective Contraceptive Methods', 'Highly Effective Contraceptive Methods That Are User', 'Failure rate of <1% per year when used consistently and correctly.', 'Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation', 'Oral.', 'Intravaginal.', 'Transdermal.', 'Progestogen only hormonal contraception associated with inhibition of ovulation', 'Oral.', 'Injectable.', 'Highly Effective Methods That Are User', 'Implantable progestogen only hormonal contraception associated with inhibition of ovulation', 'Intrauterine device (IUD).', 'Intrauterine hormone-releasing system (IUS).', 'Bilateral tubal occlusion.', 'Vasectomized Partner', 'A', 'vasectomized partner is a highly effective birth control method provided that the partner is the sole male sexual', 'partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method', 'of contraception should be used.', 'Sexual Abstinence', 'Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual', 'intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence', 'needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the subject.', 'NOTES:', 'a Typical use failure rates may differ from those when used consistently and correctly. Use should be consistent with', 'local regulations regarding the use of contraceptive methods for subjects participating in clinical studies.', 'Pregnancy Testing:', 'Women of childbearing potential should only be included after a confirmed menstrual period', 'and a negative highly sensitive serum pregnancy test at Screening and urine pregnancy test', 'on Day 1 (prior to study treatment administration).', 'Women of childbearing potential should refrain from donating oocytes for assisted', 'reproduction during this period.', 'Additional pregnancy testing should be performed as mentioned in the Schedule of Activities', '(see Section 1.3).', 'Pregnancy testing will be performed whenever a menstrual cycle is missed or when', 'pregnancy is otherwise suspected. Positive urine pregnancy test result should be confirmed', 'with serum test.', '29 October 2019', '76']\n\n###\n\n", "completion": "END"}